--- title: "Corporate Innovation Intelligence (May 10): Huolala makes another push for Hong Kong Stock Exchange IPO as commission rates continue to decline" type: "News" locale: "en" url: "https://longbridge.com/en/news/285825129.md" description: "Huolala is once again sprinting for an IPO on the Hong Kong Stock Exchange, with commission rates continuing to decline. SDGS won the property service project for BILIBILI's Binjiang headquarters. INNOVENT BIO's IBI363 has received the third designation as a breakthrough therapy from the National Medical Products Administration, for the treatment of advanced MSS/pMMR colorectal cancer. Domestic and foreign pharmaceutical companies are facing a wave of new drug development terminations. JD Fresh has established a quality alliance for beef, and Kejun Pharmaceutical has completed over RMB 300 million in Series C financing, led by WALVAX. The new BYD Seagull will be launched on May 11, equipped with lidar, with an expected increase in range" datetime: "2026-05-10T01:30:58.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285825129.md) - [en](https://longbridge.com/en/news/285825129.md) - [zh-HK](https://longbridge.com/zh-HK/news/285825129.md) --- # Corporate Innovation Intelligence (May 10): Huolala makes another push for Hong Kong Stock Exchange IPO as commission rates continue to decline ### Today's Highlights - Huolala is once again sprinting for an IPO on the Hong Kong Stock Exchange, with commission rates continuing to decline. - SDGS won the property service project for Bilibili's Binjiang headquarters. - INNOVENT BIO: IBI363 has received the third designation as a breakthrough therapy from the National Medical Products Administration, for the treatment of advanced MSS/pMMR colorectal cancer. ### Today's Intelligence (8 companies, 8 items) Huolala is once again sprinting for an IPO on the Hong Kong Stock Exchange, with commission rates continuing to decline. SDGS won the property service project for Bilibili's Binjiang headquarters. INNOVENT BIO: IBI363 has received the third designation as a breakthrough therapy from the National Medical Products Administration, for the treatment of advanced MSS/pMMR colorectal cancer. Domestic and foreign pharmaceutical companies are launching a "pipeline cutting wave," with a large number of new drugs, including those from Merck and BeiGene, being discontinued. JD Fresh has established a Wagyu Quality Alliance and launched a Wagyu Pavilion. Kejun Pharmaceutical completed over RMB 300 million in Series C financing, led by WALVAX. The new BYD Seagull will be launched on May 11, equipped with lidar, with expected improvements in range. Luxshare Precision further acquired shares in Lanyin. To review the innovation intelligence of major companies on May 9, please click on Major Companies Innovation Intelligence (May 9): Retail News: Pang Donglai announces the results of democratic evaluation; Leyou is sprinting for an IPO on the Hong Kong Stock Exchange. > Major Companies Innovation Intelligence is an information service product launched by Yiou Data, gathering innovation dynamics of well-known domestic companies and continuously tracking new technologies and models in various fields. This article is automatically published by Yiou Data's robot. If you have any questions, please contact us. > > Yiou Data is committed to providing useful industry insight tools and efficient business decision-making services for organizations that can lead technological and industrial development. If you want to customize your exclusive intelligence, please visit Yiou Data or contact us. ### Related Stocks - [002594.CN](https://longbridge.com/en/quote/002594.CN.md) - [01801.HK](https://longbridge.com/en/quote/01801.HK.md) - [09618.HK](https://longbridge.com/en/quote/09618.HK.md) - [300917.CN](https://longbridge.com/en/quote/300917.CN.md) - [300142.CN](https://longbridge.com/en/quote/300142.CN.md) - [09626.HK](https://longbridge.com/en/quote/09626.HK.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [LALA.NA](https://longbridge.com/en/quote/LALA.NA.md) - [00388.HK](https://longbridge.com/en/quote/00388.HK.md) - [BILI.US](https://longbridge.com/en/quote/BILI.US.md) - [MRK.US](https://longbridge.com/en/quote/MRK.US.md) - [06160.HK](https://longbridge.com/en/quote/06160.HK.md) - [BGNE.US](https://longbridge.com/en/quote/BGNE.US.md) - [688235.CN](https://longbridge.com/en/quote/688235.CN.md) - [JD.US](https://longbridge.com/en/quote/JD.US.md) - [01211.HK](https://longbridge.com/en/quote/01211.HK.md) - [002475.CN](https://longbridge.com/en/quote/002475.CN.md) - [LEO.DE](https://longbridge.com/en/quote/LEO.DE.md) - [80388.HK](https://longbridge.com/en/quote/80388.HK.md) - [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md) - [89618.HK](https://longbridge.com/en/quote/89618.HK.md) - [HYDD.SG](https://longbridge.com/en/quote/HYDD.SG.md) - [BYDDY.US](https://longbridge.com/en/quote/BYDDY.US.md) - [BYDDF.US](https://longbridge.com/en/quote/BYDDF.US.md) - [81211.HK](https://longbridge.com/en/quote/81211.HK.md) ## Related News & Research - [Innovent Biologics Shareholders Approve All AGM Resolutions, Strengthening Capital Flexibility](https://longbridge.com/en/news/290747206.md) - [Innovent Biologics Details Board and Committee Structure to Strengthen Governance](https://longbridge.com/en/news/290749258.md) - [Innovent Biologics files directors list with Hong Kong Stock Exchange](https://longbridge.com/en/news/290745253.md) - [Innovent doses first patient in Phase 3 China trial of IBI3003 tri-specific antibody for multiple myeloma](https://longbridge.com/en/news/290362816.md) - [Key facts: 618 GMV ¥863.6B Flat YoY; JD.com Open‑sources JoyAI‑VL](https://longbridge.com/en/news/290524732.md)